Findings

What do systematic reviews say?

317 questions · 341 findings · 38 reviews · Vascular

Sort:Best matchNewest Highest certainty Download CSV

No studies found 55 · 16.1%GRADE not reported 32 · 9.4%Very low 58 · 17%Low 117 · 34.3%Moderate 57 · 16.7%High 22 · 6.5%

Berotralstat vs placebo or active control

Quality of lifeAngioedema Quality of Life scale (lower score is better)(during · children or adults with Types I or II HAE

1 finding from 1 review

Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 130 participants
Moderate

Berotralstat vs placebo or active control

Disability standardised mean difference (lower is better) (during · children or adults with Types I or II HAE

1 finding from 1 review

Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 50 participants
Low

C1 esterase inhibitor vs placebo or active control

Improvement in quality of life: the difference in quality of life scores for participants surveyed before and after treatment · children or adults with Types I or II HAE

1 finding from 1 review

Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 36 participants
Low

Plasma‐derived C1 esterase inhibitor vs placebo or active control

Quality of lifeAngioedema Quality of Life scale (lower score is better)(during · children or adults with Types I or II HAE

1 finding from 1 review

Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 31 participants
Low

Nanofiltered C1 esterase inhibitor vs placebo or active control

Improvement in quality of life: the difference in quality of life scores for participants surveyed before and after treatment · children or adults with Types I or II HAE

1 finding from 1 review

Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 16 participants
Very low

Nanofiltered C1 esterase inhibitor vs placebo or active control

Disability standardised mean difference (lower is better) (during · children or adults with Types I or II HAE

1 finding from 1 review

Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 16 participants
Very low

Lanadelumab vs placebo or active control

Differences in quality of life ( · children or adults with Types I or II HAE

1 finding from 1 review

Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 68 participants
Low

Lanadelumab vs placebo or active control

Disability standardised mean difference (lower is better) (during · children or adults with Types I or II HAE

1 finding from 1 review

Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 64 participants
Low

Avoralstat vs placebo

Quality of lifeAngioedema Quality of Life scale (lower score is better)(during · children or adults with Types I or II HAE

1 finding from 1 review

Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 93 participants
Moderate

Prostagladin/prostacyclin analogues vs placebo

Migraine frequency Number of attacks · primary Raynaud's phenomenon

1 finding from 1 review

Vasodilators for primary Raynaud's phenomenon 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 118 participants
Low

Phlebotonics vs placebo?

Oedema in the lower legs (dichotomous variable) · patients with venous insufficiency

Do phlebotonics improve signs and symptoms of venous insufficiency… probably leads to lower oedema in the lower legs (dichotomous variable) compared with placebo? (moderate certainty).

1 finding from 1 review

Phlebotonics for venous insufficiency 2020 · Cochrane Headline outcomes only
RR 0.7 [0.63, 0.78]
13 studies · 1245 participants
Moderate

Phlebotonics vs placebo?

Oedema in the lower legs (ankle circumference, mm) · patients with venous insufficiency

1 finding from 1 review

Phlebotonics for venous insufficiency 2020 · Cochrane Headline outcomes only
no estimate extracted
15 studies · 2010 participants
Moderate

Retrievable vena caval filters with anticoagulation vs anticoagulation

Symtomatic lower extremity venous thrombosis confirmed by Doppler ultrasound or venography (up to 6 months) · participants with unprovoked acute symptomatic PE and at high risk for recurrent PEa

Retrievable vena caval filters with anticoagulation showed no clear difference in symtomatic lower extremity venous thrombosis confirmed by Doppler… compared with anticoagulation (moderate certainty).

1 finding from 1 review

Vena caval filters for the prevention of pulmonary embolism 2020 · Cochrane Headline outcomes only
RR 0.5 [0.05, 5.44]
1 study · 399 participants
Moderate

Retrievable vena caval filters with anticoagulation vs anticoagulation

Lower extremity venous thrombosis confirmed by Doppler ultrasound or venography (at 14 days) · participants who sustained multiple traumatic injuriesa

1 finding from 1 review

Vena caval filters for the prevention of pulmonary embolism 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 240 participants
Moderate

Hand‐assisted laparoscopic repair vs EVAR

Major complications ‐ lower limb ischaemia (up to 12 months) · People undergoing elective abdominal aortic aneurysm repair

Hand‐assisted laparoscopic repair showed no clear difference in major complications ‐ lower limb ischaemia (up to 12 months) compared with EVAR (low certainty).

1 finding from 1 review

Laparoscopic surgery for elective abdominal aortic aneurysm repair 2017 · Cochrane Headline outcomes only
RR 0.5 [0.05, 5.34]
1 study · 100 participants
Low

Unfractionated heparin vs low molecular weight heparin

Total VTE · people undergoing major amputation of the lower extremity

The review found no eligible studies for this question.

1 finding from 1 review

Primary prophylaxis for venous thromboembolism in people undergoing major amputation of the lower extremity 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Unfractionated heparin vs low molecular weight heparin

DVT (symptomatic, asymptomatic, non‐fatal) · people undergoing major amputation of the lower extremity

It is very uncertain whether unfractionated heparin changes DVT (symptomatic, asymptomatic, non‐fatal) (5 to 8 days after surgery) compared with low molecular weight heparin (very low certainty).

1 finding from 1 review

Primary prophylaxis for venous thromboembolism in people undergoing major amputation of the lower extremity 2020 · Cochrane Headline outcomes only
OR 1.23 [0.28, 5.35]
1 study · 75 participants
Very low

Unfractionated heparin vs low molecular weight heparin

PE (symptomatic, asymptomatic, non‐fatal) · people undergoing major amputation of the lower extremity

The review found no eligible studies for this question.

1 finding from 1 review

Primary prophylaxis for venous thromboembolism in people undergoing major amputation of the lower extremity 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Unfractionated heparin vs low molecular weight heparin

All cause mortality · people undergoing major amputation of the lower extremity

The review found no eligible studies for this question.

1 finding from 1 review

Primary prophylaxis for venous thromboembolism in people undergoing major amputation of the lower extremity 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Unfractionated heparin vs low molecular weight heparin

Adverse events · people undergoing major amputation of the lower extremity

The review found no eligible studies for this question.

1 finding from 1 review

Primary prophylaxis for venous thromboembolism in people undergoing major amputation of the lower extremity 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found